Literature DB >> 660531

The development of new iron-chelating drugs. II.

R W Grady, J H Graziano, G P White, A Jacobs, A Cerami.   

Abstract

For the past several years, we have searched for an orally effective iron-chelating drug and report here on several compounds which warrant further investigations based on their ability to promote iron excretion in the hypertransfused rat. Administrered orally, 2,3-dihydroxybenzyolglycine induced both urinary and fecal iron excretion, suggesting that a conjugate of 2,3-dihydroxybenzoic acid may be more efficacious than the parent compound. Tropolone, although rather toxic, stimulated fecal excretion of iron when given p.o. at low doses. Evaluation of less toxic derivatives of tropolone appears to be justifiable. L-Histidine may also be of use in chelatin therapy. Fecal iron excretion is significantly increased in response to oral doses of this essential amino acid. Lastly, cholylhydroxamic acid proved to be the most efficacious oral agent examined thus far. A marked increase in fecal iron excretion results from its administration.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 660531

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  Tropolone: a lipid solubilizing agent for cationic metals.

Authors:  L Hendershott; R Gentilcore; F Ordway; J Fletcher; R Donati
Journal:  Eur J Nucl Med       Date:  1982

Review 2.  Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).

Authors:  M B Agarwal
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 3.  Drug antioxidant effects. A basis for drug selection?

Authors:  B Halliwell
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.